Biodexa Pharmaceuticals Plc
BDRXDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
eRapa (encapsulated rapamycin)
Familial Adenomatous Polyposis (FAP)
Encapsulated Rapamycin (eRapa)
Familial Adenomatous Polyposis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
eRapa (encapsulated rapamycin) | Phase 3 | Familial Adenomatous Polyposis (FAP) | - | - |
Encapsulated Rapamycin (eRapa) | Phase 2 | Familial Adenomatous Polyposis | - | - |
Frequently asked questions
What is in Biodexa Pharmaceuticals Plc's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Biodexa Pharmaceuticals Plc's (BDRX) pipeline across Phase 3, Phase 2. Its lead program is eRapa (encapsulated rapamycin) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Biodexa Pharmaceuticals Plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Biodexa Pharmaceuticals Plc (BDRX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BDRX biotech catalysts?→
Add BDRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Biodexa Pharmaceuticals Plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.